First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial

Seprehvir (HSV1716) is an oncolytic herpes simplex virus-1 (HSV-1) previously demonstrated to be well tolerated in pediatric patients when administered intratumorally. To determine the safety of administering Seprehvir systemically, we conducted the first-in-human phase I trial of intravenous inject...

Descripción completa

Detalles Bibliográficos
Autores principales: Streby, Keri A., Currier, Mark A., Triplet, Melinda, Ott, Kristy, Dishman, Devon J., Vaughan, Michele R., Ranalli, Mark A., Setty, Bhuvana, Skeens, Micah A., Whiteside, Stacy, Yeager, Nicholas D., Haworth, Kellie B., Simpson, Kathleen, Conner, Joe, Cripe, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838937/
https://www.ncbi.nlm.nih.gov/pubmed/31570234
http://dx.doi.org/10.1016/j.ymthe.2019.08.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838937/
https://www.ncbi.nlm.nih.gov/pubmed/31570234
http://dx.doi.org/10.1016/j.ymthe.2019.08.020

Ejemplares similares